Medical and Psychosocial Issues in Prostate Cancer Survivors

  • Tracey L. Krupski
  • Mark S. Litwin


Of the more than 200,000 men diagnosed each year with prostate cancer in the United States,1 most live with their disease or the effects of treatment for many years.2 Although many men remain asymptomatic throughout their lives, others face a multitude of physical and psychosocial challenges. Because the duration of survival is typically long, patients and their families are particularly interested in optimizing their quality of life. At the generic level, health-related quality of life (HRQOL) encompasses an individual’s perceptions of his or her own health and ability to function in the physical, emotional, and social domains.3,4 In prostate cancer survivors, the medical outcomes of urinary, bowel, and sexual impairments that result from treatment will influence the rest of the patient’s life. The psychosocial aspects of HRQOL are impacted by the intimate nature of these medical side effects. Urinary leakage and erectile dysfunction may cause both private and public social embarrassment. In addition, such treatment-related complications may be compounded by the additional stressors associated with aging, such as retirement or death of peers.5 Nearly onethird of men diagnosed with prostate cancer in a genitourinary clinic had levels of psychologic distress that met criteria for anxiety disorder.6


Prostate Cancer Erectile Dysfunction Radical Prostatectomy Radiat Oncol Biol Phys Androgen Deprivation Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106–130.PubMedGoogle Scholar
  2. 2.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7–33.PubMedGoogle Scholar
  3. 3.
    Osoba D. Measuring the effect of cancer on quality of life. In: Osoba D (ed). Effect of Cancer on Quality of Life. Boca Raton: CRC Press, 1991:25–40.Google Scholar
  4. 4.
    Penson DF, Litwin MS. The Impact of Urologic Complications on Quality of Life. In: Taneja SS, Smith RB, Ehrlich RM, (eds). Complications of Urologic Surgery, 3rd edition. Philadelphia PA: WB Saunders and Co., 2000:56–66.Google Scholar
  5. 5.
    Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer (Phila) 1998;82(10):1904–1908.PubMedGoogle Scholar
  6. 6.
    Roth A, Scher H. Genitourinary malignancies. In: Holland JC (ed). Psycho-oncology. New York: Oxford University Press, 1998:39–358.Google Scholar
  7. 7.
    Spitz MR, Currier RD, Fueger JJ, Babaian RJ, Newell GR. Familial patterns of prostate cancer: a case-control analysis. J Urol 1991;146(5):1305–1307.PubMedGoogle Scholar
  8. 8.
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46(1):5–27.PubMedGoogle Scholar
  9. 9.
    Gilliland FD, Key CR. Prostate cancer in American Indians, New Mexico, 1969 to 1994. J Urol 1998;159(3):893–897; discussion 897–898.PubMedGoogle Scholar
  10. 10.
    Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001;93(5):388–395.PubMedGoogle Scholar
  11. 11.
    Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT. Racial/ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 2004;171(4):1504–1507.PubMedGoogle Scholar
  12. 12.
    Nayeri K, Pitaro G, Feldman JG. Marital status and stage at diagnosis in cancer. N Y State J Med 1992;92(1):8–11.PubMedGoogle Scholar
  13. 13.
    Harvei S, Kravdal O. The importance of marital and socioeconomic status in incidence and survival of prostate cancer. An analysis of complete Norwegian birth cohorts. Prev Med 1997;26(5 pt 1):623–632.PubMedGoogle Scholar
  14. 14.
    ACS. Cancer Facts and Figures. Washington, DC: American Cancer Society, 2003.Google Scholar
  15. 15.
    Zietman A, Moughan J, Owen J, Hanks G. The Patterns of Care Survey of radiation therapy in localized prostate cancer: similarities between the practice nationally and in minority-rich areas. Int J Radiat Oncol Biol Phys 2001;50(1):75–80.PubMedGoogle Scholar
  16. 16.
    Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer (Phila) 2000;88(10):2398–2424.PubMedGoogle Scholar
  17. 17.
    Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999;8(12):1117–1121.PubMedGoogle Scholar
  18. 18.
    Ross R, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst 1986;76(1):45–48.PubMedGoogle Scholar
  19. 19.
    Hargraves JL, Hadley J. The contribution of insurance coverage and community resources to reducing racial/ethnic disparities in access to care. Health Serv Res 2003;38(3):809–829.PubMedGoogle Scholar
  20. 20.
    Cunningham PJ, Kemper P. The uninsured getting care: where you live matters. Issue Brief Cent Stud Health Syst Change 1998 (15):1–6.Google Scholar
  21. 21.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969–974.PubMedGoogle Scholar
  22. 22.
    Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347(11):781–789.PubMedGoogle Scholar
  23. 23.
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–1597.PubMedGoogle Scholar
  24. 24.
    D’Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21(11):2163–2172.PubMedGoogle Scholar
  25. 25.
    Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152(5 pt 2):1837–1842.PubMedGoogle Scholar
  26. 26.
    Sylvester JE, Blasko JC, Grimm PD, Meier R, Malmgren JA. Tenyear biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003;57(4):944–952.PubMedGoogle Scholar
  27. 27.
    Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J Clin 1999;49(5):282–296.PubMedGoogle Scholar
  28. 28.
    Eastham JA, Kattan MW, Rogers E, et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156(5):1707–1713.PubMedGoogle Scholar
  29. 29.
    Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152(5 pt 2):1831–1836.PubMedGoogle Scholar
  30. 30.
    Fowler FJ Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996;14(8):2258–2265.PubMedGoogle Scholar
  31. 31.
    Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002;346(15):1138–1144.PubMedGoogle Scholar
  32. 32.
    Hu JC, Gold KF, Pashos CL, Mehta SS, Litwin MS. Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol 2003;21(3):401–405.PubMedGoogle Scholar
  33. 33.
    Walsh PC, Partin AW. Treatment of early stage prostate cancer: radical prostatectomy. Important Adv Oncol 1994:211–223.Google Scholar
  34. 34.
    Wei JT, Montie JE. Comparison of patients’ and physicians’ rating of urinary incontinence following radical prostatectomy. Semin Urol Oncol 2000;18(1):76–80PubMedGoogle Scholar
  35. 35.
    Litwin MS, McGuigan KA. Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer. J Clin Oncol 1999;17(9):2882–2888.PubMedGoogle Scholar
  36. 36.
    Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998;159(6):1988–1992.PubMedGoogle Scholar
  37. 37.
    Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 1999;54(3):503–508.PubMedGoogle Scholar
  38. 38.
    Litwin MS, Pasta DJ, Yu J, Stoddard ML, Flanders SC. Urinary function and bother after radical prostatectomy or radiation for prostate cancer: a longitudinal, multivariate quality of life analysis from the Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2000;164(6):1973–1977.PubMedGoogle Scholar
  39. 39.
    Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer (Phila) 2001;91(11):2046–2055.PubMedGoogle Scholar
  40. 40.
    Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000;55(1):58–61.PubMedGoogle Scholar
  41. 41.
    Wei JT, Dunn RL, Marcovish R, et al. Prospective assessment of patient reported urinary continence after radical prostatectomy. J Urol 2000;164(3):744–748.PubMedGoogle Scholar
  42. 42.
    Talcott JA, Rieker P, Propert KJ, et al. Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. J Natl Cancer Inst 1997;89(15):1117–1123.PubMedGoogle Scholar
  43. 43.
    Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer (Phila) 2000;88(6):1454–1463.Google Scholar
  44. 44.
    Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. J Urol 2003;170(4 pt 1):1291–1294.PubMedGoogle Scholar
  45. 45.
    Leach GE, Trockman B, Wong A, Hamilton J, Haab F, Zimmern PE. Post-prostatectomy incontinence: urodynamic findings and treatment outcomes. J Urol 1996;155(4):1256–1259.PubMedGoogle Scholar
  46. 46.
    Haab F, Yamaguchi R, Leach GE. Postprostatectomy incontinence. Urol Clin N Am 1996;23(3):447–457.Google Scholar
  47. 47.
    Lightner DJ. Review of the available urethral bulking agents. Curr Opin Urol 2002;12(4):333–338.PubMedGoogle Scholar
  48. 48.
    Smith DN, Appell RA, Rackley RR, Winters JC. Collagen injection therapy for post-prostatectomy incontinence. J Urol 1998;160(2):364–367.PubMedGoogle Scholar
  49. 49.
    Cross CA, English SF, Cespedes RD, McGuire EJ. A follow-up on transurethral collagen injection therapy for urinary incontinence. J Urol 1998;159(1):106–108.PubMedGoogle Scholar
  50. 50.
    Montague DK, Angermeier KW. Postprostatectomy urinary incontinence: the case for artificial urinary sphincter implantation. Urology 2000;55(1):2–4.PubMedGoogle Scholar
  51. 51.
    Montague DK, Angermeier KW. Artificial urinary sphincter troubleshooting. Urology 2001;58(5):779–782.PubMedGoogle Scholar
  52. 52.
    Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273(2):129–135.PubMedGoogle Scholar
  53. 53.
    Fowler FJ Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 1993;42(6):622–629.PubMedGoogle Scholar
  54. 54.
    Moul JW, Mooneyhan RM, Kao TC, McLeod DG, Cruess DF. Preoperative and operative factors to predict incontinence, impotence and stricture after radical prostatectomy. Prostate Cancer Prostatic Dis 1998;1(5):242–249.PubMedGoogle Scholar
  55. 55.
    Cohn JH, El-Galley R. Radical prostatectomy in a community practice. J Urol 2002;167(1):224–228.PubMedGoogle Scholar
  56. 56.
    Uckert S, Hedlund P, Waldkirch E, et al. Interactions between cGMP-and cAMP-pathways are involved in the regulation of penile smooth muscle tone. World J Urol 2004;22(4):261–266.PubMedGoogle Scholar
  57. 57.
    Zippe CD, Jhaveri FM, Klein EA, et al. Role of Viagra after radical prostatectomy. Urology 2000;55(2):241–245.PubMedGoogle Scholar
  58. 58.
    Zagaja GP, Mhoon DA, Aikens JE, Brendler CB. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 2000;56(4):631–634.PubMedGoogle Scholar
  59. 59.
    Costabile RA, Spevak M, Fishman IJ, et al. Efficacy and safety of transurethral alprostadil in patients with erectile dysfunction following radical prostatectomy. J Urol 1998;160(4):1325–1328.PubMedGoogle Scholar
  60. 60.
    Rodriguez VGI, Bona, AA, Benejam GJ, Cuesta P, Jioja Sanz LA. Erectile dysfunction after radical prostatectomy etiopathology and treatment. Acta Urol Esp 1997;21:909–921.Google Scholar
  61. 61.
    Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin N Am 1995;22(4):833–845.Google Scholar
  62. 62.
    Soderdahl DW, Thrasher JB, Hansberry KL. Intracavernosal druginduced erection therapy versus external vacuum devices in the treatment of erectile dysfunction. Br J Urol 1997;79(6):952–957.PubMedGoogle Scholar
  63. 63.
    Meuleman EJ, Mulders PF. Erectile function after radical prostatectomy: a review. Eur Urol 2003;43(2):95–101; discussion 101–102.PubMedGoogle Scholar
  64. 64.
    Carson CC, Mulcahy JJ, Govier FE. Efficacy, safety and patient satisfaction outcomes of the AMS 700CX inflatable penile prosthesis: results of a long-term multicenter study. AMS 700CX Study Group. J Urol 2000;164(2):376–380.PubMedGoogle Scholar
  65. 65.
    Geary ES, Dendinger TE, Freiha FS, Stamey TA. Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology 1995;45(6):1000–1006.PubMedGoogle Scholar
  66. 66.
    Kochakarn W, Ratana-Olarn K, Viseshsindh V. Vesicourethral strictures after radical prostatectomy: review of treatment and outcome. J Med Assoc Thai 2002;85(1):63–66.PubMedGoogle Scholar
  67. 67.
    Kuban D, Pollack A, Huang E, et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003;57(5):1260–1268.PubMedGoogle Scholar
  68. 68.
    Dale E, Olsen DR, Fossa SD. Normal tissue complication probabilities correlated with late effects in the rectum after prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys 1999;43(2):385–391.PubMedGoogle Scholar
  69. 69.
    Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998;51(6):991–997.PubMedGoogle Scholar
  70. 70.
    Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48(3):635–642.PubMedGoogle Scholar
  71. 71.
    Jereczek-Fossa BA, Marsiglia HR, Orecchia R. Radiotherapyrelated fatigue: how to assess and how to treat the symptom. A commentary. Tumori 2001;87(3):147–151.PubMedGoogle Scholar
  72. 72.
    Janda M, Gerstner N, Obermair A, et al. Quality of life changes during conformal radiation therapy for prostate carcinoma. Cancer 2000;89(6):1322–1328.PubMedGoogle Scholar
  73. 73.
    Wallner K, Merrick G, True L, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002;8(1):67–73.PubMedGoogle Scholar
  74. 74.
    Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol 2002;41(4):427–433.PubMedGoogle Scholar
  75. 75.
    Peschel RE, Chen Z, Roberts K, Nath R. Long-term complications with prostate implants: iodine-125 vs. palladium-103. Radiat Oncol Invest 1999;7(5):278–288.Google Scholar
  76. 76.
    Peschel RE, Colberg JW. Surgery, brachytherapy, and externalbeam radiotherapy for early prostate cancer. Lancet Oncol 2003;4(4):233–241.PubMedGoogle Scholar
  77. 77.
    Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 1999;45(1):59–67.PubMedGoogle Scholar
  78. 78.
    Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2000;48(1):119–124.PubMedGoogle Scholar
  79. 79.
    Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001;50(2):335–341.PubMedGoogle Scholar
  80. 80.
    Merrick GS, Butler WM, Tollenaar BG, Galbreath RW, Lief JH. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2002;52(2):461–468.PubMedGoogle Scholar
  81. 81.
    Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. Urology 2000;55(1):91–96.PubMedGoogle Scholar
  82. 82.
    Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001;50(5):1235–1242.PubMedGoogle Scholar
  83. 83.
    Stutz MA, Gurel MH, Moran BJ. Potency preservation after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003;57(suppl 2):S393–S394.Google Scholar
  84. 84.
    Merrick GS, Butler WM, Lief JH, Dorsey AT. Is brachytherapy comparable with radical prostatectomy and external-beam radiation for clinically localized prostate cancer? Tech Urol 2001;7(1):12–19.PubMedGoogle Scholar
  85. 85.
    Raina R, Agarwal A, Goyal KK, et al. Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate. Urology 2003;62(6):1103–1108.PubMedGoogle Scholar
  86. 86.
    Zeitlin SI, Sherman J, Raboy A, Lederman G, Albert P. High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 1998;160(1):91–95; discussion 95–96.PubMedGoogle Scholar
  87. 87.
    Jordan GH, Lynch DF, Warden SS, McCraw JD, Hoffman GC, Schellhammer PF. Major rectal complications following interstitial implantation of 125iodine for carcinoma of the prostate. J Urol 1985;134(6):1212–1214.PubMedGoogle Scholar
  88. 88.
    Theodorescu D, Gillenwater JY, Koutrouvelis PG. Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 2000;89(10):2085–2091.PubMedGoogle Scholar
  89. 89.
    Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 2000;57(3):273–278.PubMedGoogle Scholar
  90. 90.
    D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer (Phila) 2002;95(2):281–286.PubMedGoogle Scholar
  91. 91.
    D’Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 2000;284(10):1280–1283.PubMedGoogle Scholar
  92. 92.
    D’Amico AV, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J Urol 2000;163(6):1797–1801.PubMedGoogle Scholar
  93. 93.
    Talcott JA, Clark JA, Stark PC, Mitchell SP. Long-term treatment related complications of brachytherapy for early prostate cancer: a survey of patients previously treated. J Urol 2001;166(2):494–499.PubMedGoogle Scholar
  94. 94.
    Ghaly M, Wallner K, Merrick G, et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys 2003;55(5):1288–1293.PubMedGoogle Scholar
  95. 95.
    Wang H, Wallner K, Sutlief S, Blasko J, Russell K, Ellis W. Transperineal brachytherapy in patients with large prostate glands. Int J Cancer 2000;90(4):199–205.PubMedGoogle Scholar
  96. 96.
    Sacco DE, Daller M, Grocela JA, Babayan RK, Zietman AL. Corticosteroid use after prostate brachytherapy reduces the risk of acute urinary retention. BJU Int 2003;91(4):345–349.PubMedGoogle Scholar
  97. 97.
    Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Prostate Cancer Prostatic Dis 1999;2(S3):S32.PubMedGoogle Scholar
  98. 98.
    Downs TM, Sadetsky N, Pasta DJ, et al. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer: data from CaPSURE. J Urol 2003;170(5):1822–1827.PubMedGoogle Scholar
  99. 99.
    Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20(2):557–566.PubMedGoogle Scholar
  100. 100.
    Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer (Phila) 2001;92(6):1451–1459.PubMedGoogle Scholar
  101. 101.
    Davis JW, Kuban DA, Lynch DF, Schellhammer PF. Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 2001;166(3):947–952.PubMedGoogle Scholar
  102. 102.
    Van Andel G, Visser AP, Hulshof MC, Horenblas S, Kurth KH. Health-related quality of life and psychosocial factors in patients with prostate cancer scheduled for radical prostatectomy or external radiation therapy. BJU Int 2003;92(3):217–222.PubMedGoogle Scholar
  103. 103.
    Saigal CS, Gornbein J, Reid K, Litwin MS. Stability of time tradeoff utilities for health states associated with the treatment of prostate cancer. Qual Life Res 2002;11(5):405–414.PubMedGoogle Scholar
  104. 104.
    Gray RE, Fitch MI, Phillips C, Labrecque M, Klotz L. Presurgery experiences of prostate cancer patients and their spouses. Cancer Pract 1999;7(3):130–135.PubMedGoogle Scholar
  105. 105.
    Baider L, Walach N, Perry S, Kaplan De-Nour A. Cancer in married couples: higher or lower distress? J Psychosom Res 1998;45(3):239–248.PubMedGoogle Scholar
  106. 106.
    Hagedoorn M, Buunk BP, Kuijer RG, Wobbes T, Sanderman R. Couples dealing with cancer: role and gender differences regarding psychological distress and quality of life. Psycho-Oncology 2000;9(3):232–242.PubMedGoogle Scholar
  107. 107.
    Funch DP, Marshall J. The role of stress, social support and age in survival from breast cancer. J Psychosom Res 1983;27(1):77–83.PubMedGoogle Scholar
  108. 108.
    Greer S, Watson M. Towards a psychobiological model of cancer: psychological considerations. Soc Sci Med 1985;20(8):773–777.PubMedGoogle Scholar
  109. 109.
    Massie MJ, Shakin EJ. Management of depression and anxiety in the cancer patient. In: Breitbart W, Holland JC (eds). Psychiatric Aspects of Symptoms Management in Cancer Patients. Washington, DC: American Psychiatric Press, 1993:1–21.Google Scholar
  110. 110.
    McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995;52(2):89–99.PubMedGoogle Scholar
  111. 111.
    Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med 1984;46(3):199–212.PubMedGoogle Scholar
  112. 112.
    Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer (Phila) 1994;73(11):2791–2802.PubMedGoogle Scholar
  113. 113.
    Bisson JI, Chubb HL, Bennett S, Mason M, Jones D, Kynaston H. The prevalence and predictors of psychological distress in patients with early localized prostate cancer. BJU Int 2002;90(1):56–61.PubMedGoogle Scholar
  114. 114.
    Davison BJ, Goldenberg SL. Decisional regret and quality of life after participating in medical decision-making for early-stage prostate cancer. BJU Int 2003;91(1):14–17.PubMedGoogle Scholar
  115. 115.
    Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92(19):1582–1592.PubMedGoogle Scholar
  116. 116.
    Hu JC, Kwan L, Saigal CS, Litwin MS. Regret in men treated for localized prostate cancer. J Urol 2003;169(6):2279–2283.PubMedGoogle Scholar
  117. 117.
    Clark JA, Wray NP, Ashton CM. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. J Clin Oncol 2001;19(1):72–80.PubMedGoogle Scholar
  118. 118.
    Clark JA, Wray N, Brody B, Ashton C, Giesler B, Watkins H. Dimensions of quality of life expressed by men treated for metastatic prostate cancer. Soc Sci Med 1997;45(8):1299–1309.PubMedGoogle Scholar
  119. 119.
    Mehta SS, Lubeck DP, Pasta DJ, Litwin MS. Fear of cancer recurrence in patients undergoing definitive treatment for prostate cancer: results from CaPSURE. J Urol 2003;170(5):1931–1933.PubMedGoogle Scholar
  120. 120.
    McNair DM, Lorr M, Droppleman CF. Manual: Profile of Mood States, 2nd ed. San Diego: Educational and Industrial Testing Service, 1981.Google Scholar
  121. 121.
    Ullrich PM, Carson MR, Lutgendorf SK, Williams RD. Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J Urol 2003;169(4):1449–1452.PubMedGoogle Scholar
  122. 122.
    Roth AJ, Rosenfeld B, Kornblith AB, et al. The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with prostate cancer. Cancer (Phila) 2003;97(11):2910–2918.PubMedGoogle Scholar
  123. 123.
    Wallace M. Uncertainty and quality of life of older men who undergo watchful waiting for prostate cancer. Oncol Nurs Forum 2003;30(2):303–309.PubMedGoogle Scholar
  124. 124.
    Kaps EC. The role of the support group, “Us Too”. Cancer (Phila) 1994;74(suppl 7):2188–2189.PubMedGoogle Scholar
  125. 125.
    Kunkel EJ, Bakker JR, Myers RE, Oyesanmi O, Gomella LG. Biopsychosocial aspects of prostate cancer. Psychosomatics 2000;41(2):85–94.PubMedGoogle Scholar
  126. 126.
    Austin JP, Aziz H, Potters L, et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol 1990;13(6):465–469.PubMedGoogle Scholar
  127. 127.
    Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 pt 2):1821–1825.PubMedGoogle Scholar
  128. 128.
    Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5 pt 2):1850–1857.PubMedGoogle Scholar
  129. 129.
    Abi-Aad AS, Macfarlane MT, Stein A, deKernion JB. Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound. J Urol 1992;147(3 pt 2):952–955.PubMedGoogle Scholar
  130. 130.
    Paulson DF. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152(5 pt 2):1826–1830.PubMedGoogle Scholar
  131. 131.
    ASTRO. Consensus Statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997;37:1035–1041.Google Scholar
  132. 132.
    Noble RL. Hormonal control of growth and progression in tumors of Nb rats and a theory of action. Cancer Res 1977;37(1):82–94.PubMedGoogle Scholar
  133. 133.
    Schroder FH. Endocrine treatment of prostate cancer: recent developments and the future. Part 1: maximal androgen blockade, early vs. delayed endocrine treatment and side-effects. BJU Int 1999;83(2):161–170.PubMedGoogle Scholar
  134. 134.
    Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502–508.PubMedGoogle Scholar
  135. 135.
    Iversen P. Quality of life issues relating to endocrine treatment options. Eur Urol 1999;36(suppl 2):20–26.PubMedGoogle Scholar
  136. 136.
    Denis LJ, Carnelro de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42(2):119–129; discussion 129–130.PubMedGoogle Scholar
  137. 137.
    Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321(7):419–424.PubMedGoogle Scholar
  138. 138.
    Denis L, Murphy GP. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer. Cancer (Phila) 1993;72(suppl 12):3888–3895.PubMedGoogle Scholar
  139. 139.
    Seidenfeld J, Samson DJ, Aronson N, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ) 1999 (4):i–x, 1–246, I241–236, passim.Google Scholar
  140. 140.
    Bolla M, de Reijke TM, Zurlo A, Collette L. Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials. Front Radiat Ther Oncol 2002;36:81–86.PubMedGoogle Scholar
  141. 141.
    Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999;341(24):1781–1788.PubMedGoogle Scholar
  142. 142.
    Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995;16(1):87–116.PubMedGoogle Scholar
  143. 143.
    Niewoehner CB. Osteoporosis in men. Is it more common than we think? Postgrad Med 1993;93(8):59–60, 63–70.PubMedGoogle Scholar
  144. 144.
    Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer (Phila) 1997;79(3):545–550.PubMedGoogle Scholar
  145. 145.
    Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000;86(4):449–452.PubMedGoogle Scholar
  146. 146.
    Melton LJ III, Alothman KI, Khosla S, Achenbach SJ, Oberg AL, Zincke H. Fracture risk following bilateral orchiectomy. J Urol 2003;169(5):1747–1750.PubMedGoogle Scholar
  147. 147.
    Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997;157(2):439–444.PubMedGoogle Scholar
  148. 148.
    Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9(8):1137–1141.PubMedGoogle Scholar
  149. 149.
    Finkelstein JS, Klibanski A, Neer RM, Greenspan SL, Rosenthal DI, Crowley WF Jr. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann Intern Med 1987;106(3):354–361.PubMedGoogle Scholar
  150. 150.
    Berruti A, Dogliotti L, Terrone C, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002;167(6):2361–2367; discussion 2367.PubMedGoogle Scholar
  151. 151.
    Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345(13):948–955.PubMedGoogle Scholar
  152. 152.
    Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin N Am 1998;27(2):349–367.Google Scholar
  153. 153.
    Daniell HW. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 2001;58(2 suppl 1):101–107.PubMedGoogle Scholar
  154. 154.
    Higano CS. Management of bone loss in men with prostate cancer. J Urol 2003;170(6 pt 2):S59–S63; discussion S64.PubMedGoogle Scholar
  155. 155.
    Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343(9):604–610.PubMedGoogle Scholar
  156. 156.
    Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer (Phila) 1998;83(8):1561–1566.PubMedGoogle Scholar
  157. 157.
    Higano CS. Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urol Oncol 2003;21(5):392–398.PubMedGoogle Scholar
  158. 158.
    Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169(6):2008–2012.PubMedGoogle Scholar
  159. 159.
    Vogelzang NJ, Breitbart W, Cella D, et al. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 1997;34(3 suppl 2):4–12.PubMedGoogle Scholar
  160. 160.
    Engelson ES, Rabkin JG, Rabkin R, Kotler DP. Effects of testosterone upon body composition. J Acquir Immune Defic Syndr Hum Retrovirol 1996;11(5):510–511.PubMedGoogle Scholar
  161. 161.
    Stone P, Hardy J, Huddart R, A’Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000;36(9):1134–1141.PubMedGoogle Scholar
  162. 162.
    Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46(10):1121–1123.PubMedGoogle Scholar
  163. 163.
    Stone P, Richards M, A’Hern R, Hardy J. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manag 2001;22(6):1007–1015.Google Scholar
  164. 164.
    Pawlikowska T, Chalder T, Hirsch SR, Wallace P, Wright DJ, Wessely SC. Population based study of fatigue and psychological distress. BMJ 1994;308(6931):763–766.PubMedGoogle Scholar
  165. 165.
    Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79(6):933–941.PubMedGoogle Scholar
  166. 166.
    Herr HW, Kornblith AB, Ofman U. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer (Phila) 1993;71(suppl 3):1143–1150.PubMedGoogle Scholar
  167. 167.
    Blanchard CG, Albrecht TL, Ruckdeschel JC. The crisis of cancer: psychological impact on family caregivers. Oncology (Williston Park) 1997;11(2):189–194; discussion 196, 201–202.Google Scholar
  168. 168.
    Valdimarsdottir U, Helgason AR, Furst CJ, Adolfsson J, Steineck G. The unrecognised cost of cancer patients’ unrelieved symptoms: a nationwide follow-up of their surviving partners. Br J Cancer 2002;86(10):1540–1545.PubMedGoogle Scholar
  169. 169.
    Perry PJ, Yates WR, Williams RD, et al. Testosterone therapy in late-life major depression in males. J Clin Psychiatry 2002;63(12):1096–1101.PubMedGoogle Scholar
  170. 170.
    Pirl WF, Siegel GI, Goode MJ, Smith MR. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psycho-Oncology 2002;11(6):518–523.PubMedGoogle Scholar
  171. 171.
    Litwin MS, Lubeck DP, Stoddard ML, Pasta DJ, Flanders SC, Henning JM. Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol 2001;165(3):871–875.PubMedGoogle Scholar
  172. 172.
    Melmed GY, Kwan L, Reid K, Litwin MS. Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology 2002;59(1):103–109.PubMedGoogle Scholar
  173. 173.
    Morris JN, Suissa S, Sherwood S, Wright SM, Greer D. Last days: a study of the quality of life of terminally ill cancer patients. J Chronic Dis 1986;39(1):47–62.PubMedGoogle Scholar
  174. 174.
    Steinhauser KE, Christakis NA, Clipp EC, McNeilly M, McIntyre L, Tulsky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA 2000;284(19):2476–2482.PubMedGoogle Scholar
  175. 175.
    Saunders Y, Ross JR, Riley J. Planning for a good death: responding to unexpected events. BMJ 2003;327(7408):204–206; discussion 206–207.PubMedGoogle Scholar
  176. 176.
    Murphy GP, Mettlin C, Menck H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994;152(5 pt 2):1817–1819.PubMedGoogle Scholar
  177. 177.
    Talcott JA, Rieker P, Clark JA, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998;16(1):275–283.PubMedGoogle Scholar
  178. 178.
    Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283(3):354–360.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Tracey L. Krupski
    • 1
  • Mark S. Litwin
    • 2
  1. 1.Department of UrologyDale University Medical SchoolDurhamUSA
  2. 2.Department of Urology and Health Services, David Geffen School of Medicine, School of Public Health, Jonsson Comprehensive Cancer CenterUniversity of CaliforniaLos AngelesUSA

Personalised recommendations